Table 1 Baseline characteristics of subjects in the internal validation dataset.

From: A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients

Variables

All patients (n = 752)

Low-risk* (n = 232)

High-risk* (n = 520)

P-value

Median follow-up (Months)

95.8 (0.6–169.3)

95.8 (0.6–169.3)

95.8 (0.9–164.5)

0.2525

Menstruation status

   

<0.0001

   Pre-menopausal

481

138 (59.5%)

343 (66.0%)

 

   Post-menopausal

262

91 (39.2%)

171 (32.9%)

 

   Unknown

9

3 (1.3%)

6 (1.2%)

 

Age

   

<0.0001

   <40

138

25 (10.8%)

113 (21.7%)

 

   41–50

279

101 (43.5%)

178 (34.2%)

 

   51–60

223

58 (25.0%)

165 (31.7%)

 

   >60

112

48 (20.7%)

64 (12.3%)

 

T stage

   

<0.0001

   T1

327

152 (65.5%)

175 (33.7%)

 

   T2

408

76 (32.8%)

332 (63.9%)

 

   T3

17

4 (1.7%)

13 (2.5%)

 

N stage

   

<0.0001

   N0

364

152 (65.5%)

212 (40.8%)

 

   N1

282

67 (28.9%)

215 (41.4%)

 

   N2

106

13 (5.6%)

93 (17.9%)

 

ER and PR status

   

<0.0001

   Both Negative

260

14 (6.0%)

246 (47.3%)

 

   ER or PR (+)

492

218 (94.0%)

274 (52.7%)

 

HER2 overexpression

   

<0.0001*

   Negative

492

198 (85.3%)

294 (56.5%)

 

   Positive

257

34 (14.7%)

223 (42.9%)

 

   Indeterminant

3

0 (0.0%)

3 (0.6%)

 

LVI

   

<0.0001

   Absent/focal

582

201 (86.6%)

381 (73.3%)

 

   Prominent

170

31 (13.4%)

139 (26.7%)

 

Tumour grade

   

<0.0001

   Grade I

83

74 (31.9%)

9 (1.7%)

 

   Grade II

238

123 (53.0%)

115 (22.1%)

 

   Grade III

431

35 (15.1%)

396 (76.2%)

 

PMRT or RNI

   

<0.0001

   No

184

78 (33.6%)

106 (20.4%)

 

   Yes

568

154 (66.4%)

414 (79.6%)

 

Adjuvant C/T

   

<0.0001

   No

82

54 (23.3%)

28 (5.4%)

 

   Yes

670

178 (76.7%)

492 (94.6%)

 

Adjuvant H/T

   

<0.0001

   No

281

20 (8.6%)

261 (50.2%)

 

   Yes

471

212 (91.4%)

259 (49.8%)

 

Adjuvant trastuzumab

   

<0.0001

   No

655

220 (94.8%)

435 (83.7%)

 

   Yes

97

12 (5.2%)

85 (16.4%)

 

IHC subtype

   

<0.0001

   ER/PR+ HER2−, Gr 1–2

249

171(73.7%)

78 (15.0%)

 

   ER/PR+ HER2−, Gr 3

89

19 (8.2%)

70 (13.5%)

 

   ER/PR+ HER2+ 

152

28 (12.1%)

124 (23.9%)

 

   ER−, PR−, HER2+ 

105

6 (2.6%)

99 (19.0%)

 

   ER−, PR−, HER2−

154

8 (3.5%)

146 (28.1%)

 

PAM50 intrinsic subtypes

   

<0.0001

   Luminal A

192

148 (63.8%)

44 (8.5%)

 

   Luminal B

212

43 (18.5%)

169 (32.5%)

 

   HER2

140

1 (0.4%)

139 (26.7%)

 

   Basal

144

2 (0.9%)

142 (27.3%)

 

   Normal

64

38 (16.4%)

26 (5.0%)

 
  1. *Defined by DGM-CM6: cutoff <33 as low-risk, \(\ge \)33 as high-risk.
  2. BCS, breast-conserving surgery; C/T, chemotherapy; H/T, hormonal therapy; LVI, lymphovascular invasion; MRM, modified radical mastectomy; PMRT, post-mastectomy radiotherapy; RNI, regional node irradiation.
Back to article page